Chronic obstructive pulmonary disease (COPD) is a disabling condition associated with progressive airflow limitation that is largely irreversible, with symptoms of dyspnoea, cough and sputum production. In the Netherlands, COPD tends to be underpresented to physicians, underdiagnosed and under-treated by healthcare professionals, and poorly recognized among the general population. Improving the diagnosis and management of COPD in this country may require raised awareness of the impact of the disease on society.This may be achieved by providing detailed information on the burden of COPD on the patient, healthcare system and the economyThis information has now become available from Confonting COPD in North America and Europe, the first international survey to quantify the country-specific impact of the disease. An economic analysis of the results of the Dutch survey revealed the high cost of COPD to the healthcare system and society, with direct costs estimated at e6 I4 per patient. Indirect costs amounted to E4 IO, bringing the annual per patient cost of COPD to E 1024. Around 50% of the cost of COPD to the healthcare system was for prescription medication, including symptomatic medication and treatment for underlying airway inflammation. This contributed to effective symptom control in many patients, as shown by the low utilization of unscheduled healthcare (inpatient hospitalizations, emergency room visits, or contacts with healthcare professionals). However; the survey suggested that there was scope for improvement in the understanding of the origin and consequences of this disease among the general public, and the way COPD is managed by healthcare professionals, in order to increase the proportion of patients who are diagnosed with COPD and treated in accordance with management guidelines. In addition, smoking cessation intervention at the early stages of the disease could help to reduce the high costs associated with severe COPD in this country,
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is a disabling condition associated with progressive airflow limitation that is largely irreversible, with symptoms of dyspnoea, cough and sputum production. Tobacco smoking is the single most important cause of the disease (I). In the Netherlands, it is difficult to quantify how many people are affected with COPD, as little differentiation has been made between COPD and asthma, either by physicians or by researchers conducting epidemiological studies in the general population (2). However, based on patient data from general practice registers, the overall prevalence of COPD was estimated at 2.4% for men, and I .4% for women in 2000.The prevalence of the disease increases with age, with the highest rates seen in people over the age of 75 years (I 6% in men and 4.4% in women) (3). A modelling analysis that assessed the future burden of COPD in the Netherlands predicted that changes in the size and composition of the population would increase the prevalence of COPD to 3.3% in men and 2.3% in women by 20 I5 (a 59% increase in COPD prevalence in men and a 123% increase in women from the 1994 figures) (3). When smoking patterns were taken into account, the predicted prevalence rate dropped to 2.9% for men (due to recent decline in the proportion of men who are smoke), but rose to 2.5% in women (reflecting the long-term cumulative impact of an increase in smoking prevalence among women over the past few decades).
COPD causes considerable mortality and morbidity worldwide, and is predicted to become the fourth leading cause of death and the fifth leading cause of disability by the year 2020 (4). Studies in other countries have shown that mortality and morbidity from COPD has an impact on the society, in terms of the direct costs associated with healthcare resource use, and indirect costs due to lost productivity resulting from illness, RESPlR4TORY MEDICINE disability and premature death (5-7). In the Netherlands, studies that have attempted to assess the burden of COPD have focused on direct costs. A prevalence-based cost-of-illness study estimated the total direct costs of COPD and asthma at US$346 million in 1993, with an annual cost of US$876 per patient with COPD, compared with US$499 for asthma (8) . When the costs of asthma and COPD were entered into a lifetime epidemiological model, it was estimated that the direct cost of these diseases would rise by 60% by the year 2010, to US$555 mil1ion.A modelling analysis based on prevalence data and smoking rates estimated that the direct cost of the disease in the Netherlands would rise by 90% between 1994 (US$300 million) and 20 I5 (US$580 million), primarily as a result of healthcare resource utilization in current or former smokers with the disease (3).
The results of the cost-of-illness study described above revealed that the majority of costs for COPD were associated with hospital care (COPD accounted for 86% of inpatient costs for asthma and COPD combined) (8). The higher costs of hospitalization for patients with COPD compared with asthma were due to the higher number of inpatient days (381 194 versus 99 I 14) and, in particular, a longer duration of hospital stay (I 6.0 days versus 9.2 days). As acute exacerbations of COPD are a major cause of inpatient hospitalization, these results suggest that improved management of exacerbations in primary care may reduce the burden of COPD on the healthcare system. A study of physician practices in the Netherlands in 1998 showed that the management of COPD exacerbations in primary care did not concord with Dutch management guidelines, with overutilization of antibiotic therapy, and only limited use of anti-inflammatory medications (inhaled and systemic corticosteroids) (9). The underpresentation of patients to physicians, and the underdiagnosis and subsequent undertreatment of COPD may also contribute to the burden of the disease in the Netherlands. It has been estimated that more than 50% of patients with asthma/COPD do not recognize that they have a disease so do not present to a physician, so they remain undiagnosed and do not receive prescribed medication to control the chronic symptoms of the disease (IO). In a recent survey of the Dutch population, 95% of people questioned did not know what COPD was (I I). Even when patients do contact their physician, COPD may go undetected or be misdiagnosed as asthma, as lung function tests are rarely conducted in primary care (I 2).
improving the diagnosis and management of COPD in the Netherlands may rely on raising awareness about the impact of the disease on society.This may be achieved by providing detailed information on the burden of COPD on the patient, healthcare system and the economy.This information has now become available from Confronting COPD in North America and Europe, the first international survey to quantify the country-specific impact of the disease.The survey interviewed patients and physicians in eight countries, to collect information on clinical outcomes, healthcare resource utilization and direct costs, COPD-related productivity loss, and indirect costs resulting from patient work absence.The clinical results of the survey showed that many patients with COPD were underdiagnosed and undertreated, and suffered frequent and disabling symptoms that reduced their quality of life (I 3).This paper reports the results of the economic analysis of the data on healthcare resource utilization and lost productivity in the Netherlands.
METHODS

Survey details
The methodology for economic analysis of the Confronting COPD survey is described elsewhere (14). In brief, telephone interviews were conducted with a total of 3265 patients with COPD and 905 physicians in the Netherlands and seven other countries (Canada, France, Germany, Italy, Spain, the U.K., and the U.S.A.). Patient responses to the survey questionnaire were used to derive quantitative measures of COPD-related healthcare resource use and lost productivity.
Direct, indirect and total societal costs per patient were calculated for the survey sample from each country (with the exception of Germany).A sub-analysis of costs was conducted for patient groups stratified by disease severity, sex, smoking status, comorbidity and education level.
Cost calculations
The unit costs used in the economic analysis of the survey data from the Netherlands are shown in Table I . Unit costs for lost productivity were applied to patients below the age of 62 years (the standard age of retirement for men and women in this country). The friction-cost method was used to calculate mean per patient costs of time lost from work, as described elsewhere ( 14). (Table 3) .
RESULTS
Patient demographics
Two-fifths (42%) of patients in the sample were under specialist care for the treatment of their condition, and one-quarter of patients (27%) had seen a respiratory specialist at least three times in the past I2 months.The total number of specialist visits was 73 I, most of which were reported as either scheduled or unscheduled visits (Table 3) . Unscheduled specialist visits were reported by 4% of patients (mean seven visits per patient in this group), with a mean of 0.52 visits in the survey sample.
Over one-quarter (27%) of patients in the survey reported that they had been hospitalized for COPD, with 9% of patients having an in-patient stay in the last I 2 months. A total of I I4 hospitalizations were reported (Table 4 ). Emergency room visits were reported by 6% of patients, with I89 visits in the past year.
Almost three-quarters (73%) of the patients in the Netherlands sample were currently receiving regular prescription medication for COPD. Inhaled corticosteroids were the most commonly prescribed drugs, with short-acting &-agonists, anticholinergics and longacting &-agonists received by over one-quarter of patients ( Fig. I) . One-fifth of patients had a nebulizer for drug administration.
Six patients were prescribed a smoking cessation aid (bupropion).
Around two-fifths (38%) of patients had been treated with antibiotics for respiratory infections in the previous year.The mean number of courses per patient reporting antibiotic use was 2.24 (mean 0.86 for the entire survey sample).The majority of patients (71%) had an influenza vaccination in the previous year, aimed at preventing exacerbations of COPD. Home oxygen therapy for COPD was used by 4% of patients (n= IS) in the last I2 months, with 4 I35 days of use (mean 276 days use for each patient using oxygen therapy).
The Confronting COPD survey also assessed the number of laboratory tests received by patients with . The most commonly reported investigation was the chest X-ray, followed by tests of blood oxygen levels (Table 5 ).
Time lost from work
Over half (60%) of patients in the Netherlands survey sample were under the age of retirement. Just under one-fifth (18%) of patients reported that they were completely prevented from working due to COPD, and one in ten patients (10%) reported that they were limited in their work during the I2 months prior to the survey.A further 3% of patients missed work as a result of their condition, with a total of 4894 days lost in the past year. Twelve patients (3%) reported that their caregiver missed work as a result of COPD, with a total of 65 days lost (mean 5.4 days per caregiver).
Direct costs
Based on measures of healthcare resource utilization, the mean annual direct cost of COPD was estimated at E6 13.92 per patient. Almost three-fifths of these costs were accounted for by treatment for COPD (mean 8359.70 per patient), of which prescription medication amounted to e300.93 (Fig. 2, Table 6 ). Unscheduled emergency care for COPD (inpatient hospitalizations, emergency room visits, unscheduled PCP and specialist visits) accounted for over one-fifth (2 I%) of costs, compared with 16% of total costs for scheduled visits to a healthcare professional (Fig. 2) . Specialist visits accounted for a higher proportion of direct per patient costs than inpatient hospitalizations, emergency room treatment, or PCP visits alone (Table 6 ). Laboratory tests for COPD accounted for under 4% of direct costs, at a mean cost of 822.05 per patient.
Indirect and total societal costs
The results of the Confronting COPD survey in the Netherlands revealed that patient work loss due to COPD cost an estimated E409.70 per patient over a I2-month period.When the indirect cost of COPD was added to the direct cost (see above), the societal cost of COPD was estimated at +Z 1023.62 per patient.
Costs sub-analysis
A sub-analysis of direct, indirect and societal costs was carried out to assess the economic impact of COPD in relation to disease severity. The results showed that patients with severe COPD (either self-perceived or assessed using the Medical Research Council Dyspnoea Scale) had consistently higher costs than patients with moderate or mild COPD (Fig. 3) .
Costs were also assessed in relation to patient sex, smoking status, comorbidity and education level. The results showed that direct, indirect, and societal costs per patient were higher for male patients, former smokers, patients with comorbidities and patients with no education beyond basic schooling, compared with female for the treatment of their condition.Twofifths of patients were also under specialist care. Seven of ten COPD patients in the current survey had received an influenza vaccination in the previous year. Regular prescription medication for COPD was reported by 75% of patients in the survey, and inhaled corticosteroids were the most commonly prescribed medication class (being reported by almost half of the patients in the survey sample).The use of inhaled corticosteroids in the treatment of COPD is widely accepted in the Netherlands, based on the concept of treating the inflammatory component of COPD, with the aim of reducing exacerbations of this disease (I 5).This concept has now been included in the General Practitioner guidelines for the diagnosis and the treatment of COPD in this country (I 6-l 7).
Aside from inhaled corticosteroids, over one-quarter of patients in the survey reported treatment with shortacting PI-agonists, anticholinergics and long-acting &-agonists. The results of the survey suggested that treatment of the symptoms and the underlying airway inflammation in COPD may lead to effective disease control. Fewer than one in ten patients in the survey had been hospitalized for COPD in the previous year, and hospitalization accounted for only 12% of the direct costs of the disease, compared with 50% for regular prescription medication. This contrasts with previous cost-of-illness studies conducted in the Netherlands, where the majority of direct costs were for hospitalization (8) . Although the apparent shift from hospitalizations to medication as a major cost driver could have resulted from restrictive hospitalization policy, or different definitions of COPD being adopted during the period between this and previous studies, the low rate of hospitalization in the current survey was accompanied by a low number of unscheduled visits to physicians (l3), suggesting that improved control of COPD symptoms with bronchodilator and antiinflammatory medications was a contributory factor. Only a small proportion of patients in the survey reported unscheduled care for COPD (i.e. hospitalizations, emergency room visits and unscheduled contacts with healthcare professionals). Recognizing that COPD is a heterogeneous disease, it is possible that in these patients, the underlying aetiology of COPD is such that current treatment is unable to prevent unscheduled events. Research is required to investigate this further. Identifying sub-groups of patients who may be unresponsive to treatment could be important from a healthcare evaluation perspective, as disease aetiology and the lack of effective treatment, rather than healthcare services provided, may determine outcomes in these patients. If such sub-groups of patients were identified, developing effective treatments to prevent unscheduled events could reduce the economic impact of COPD in the Netherlands, as over one-fifth of direct per patient costs in the survey were due to unscheduled care.
One-fifth of patients in the survey had not been diagnosed with COPD, and were presumably not receiving regular prescribed treatment for the chronic symptoms of the disease. Both from a healthcare and an economic perspective, reducing the number of undiagnosed COPD patients could play an important role in alleviating the burden of this disease. Many patients may remain undiagnosed because they do not present to a physician with symptoms of the disease. Therefore, an increased understanding of the origin, the consequences and treatment of COPD among the general public could help to increase the number of patients who receive a diagnosis.
A study conducted in I998 among 24 primary care practitioners in the Netherlands revealed barriers to the implementation of guideline recommendations for asthma/COPD. However, by monitoring physicians and providing them with feedback on their provision of care, physicians showed improvement in their knowledge and skills surrounding diagnosis and treatment of COPD, with an increase in the monitoring of lung function, the use of influenza vaccination to prevent respiratory infection, and the treatment of exacerbations with antiinflammatory medications, rather than antibiotics (9,I2). These results suggest that recognizing the nature of barriers to the implementation of guidelines and developing initiatives to overcome them will contribute to improved primary care provision for COPD patients.
The sub-analysis of costs from Confronting COPD in the Netherlands showed that the direct, indirect and total societal costs of COPD were considerably higher in patients with severe disease than patients with mild or moderate COPD. This suggests that interventions that could effectively delay the progression to severe COPD could reduce the costs of the disease. At present, smoking cessation in the early stages of COPD is the only intervention proven to delay the long-term decline in lung function in these patients. The importance of smoking cessation in patients with COPD has already been highlighted by an analysis of the future burden of the disease in the Netherlands, which estimated that smoking behaviour would account for 90% of the increase in direct costs that is predicted to occur by 20 I5 (3).
CONCLUSION
COPD is a disease that places a high burden on the healthcare system and society in the Netherlands. Unlike in previous studies, treatment for COPD accounted for a significant proportion of costs of COPD to the healthcare system, and the burden of COPD on unscheduled emergency care was relatively low. The survey suggested that there is scope to improve the proportion of diagnosed COPD patientsThis could be achieved by increasing the understanding of the origin and the consequences of this disease among the general public.
Recognizing and developing strategies to overcome barriers to the implementation of treatment guidelines would support the provision of improved primary care services for COPD. In addition, smoking cessation intervention at the early stages of the disease could help to reduce the high costs associated with severe COPD in this country. 
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